136 related articles for article (PubMed ID: 22391574)
1. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib, a small-molecule receptor tyrosine kinase inhibitor, suppresses neointimal hyperplasia in balloon-injured rat carotid artery.
Ishii S; Okamoto Y; Katsumata H; Egawa S; Yamanaka D; Fukushima M; Minami S
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):359-66. PubMed ID: 23324994
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.
Abouantoun TJ; Castellino RC; MacDonald TJ
J Neurooncol; 2011 Jan; 101(2):215-26. PubMed ID: 20524040
[TBL] [Abstract][Full Text] [Related]
5. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
Catena R; Luis-Ravelo D; Antón I; Zandueta C; Salazar-Colocho P; Larzábal L; Calvo A; Lecanda F
Cancer Res; 2011 Jan; 71(1):164-74. PubMed ID: 21097719
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract][Full Text] [Related]
7. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.
Pfister C; Pfrommer H; Tatagiba MS; Roser F
Br J Cancer; 2012 Nov; 107(10):1702-13. PubMed ID: 23047550
[TBL] [Abstract][Full Text] [Related]
10. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis.
Majumder S; Piguet AC; Dufour JF; Chatterjee S
Eur J Pharmacol; 2013 Apr; 705(1-3):86-95. PubMed ID: 23454556
[TBL] [Abstract][Full Text] [Related]
11. A novel PDGF receptor inhibitor-eluting stent attenuates in-stent neointima formation in a rabbit carotid model.
Huang C; Mei H; Zhou M; Zheng X
Mol Med Rep; 2017 Jan; 15(1):21-28. PubMed ID: 27922693
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
[TBL] [Abstract][Full Text] [Related]
15. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Christensen JG
Ann Oncol; 2007 Sep; 18 Suppl 10():x3-10. PubMed ID: 17761721
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
17. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Mahboobi S; Uecker A; Sellmer A; Cénac C; Höcher H; Pongratz H; Eichhorn E; Hufsky H; Trümpler A; Sicker M; Heidel F; Fischer T; Stocking C; Elz S; Böhmer FD; Dove S
J Med Chem; 2006 Jun; 49(11):3101-15. PubMed ID: 16722630
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2007 May; 356(2):323-8. PubMed ID: 17367763
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
